What is MicroSure?
Founded in 2016 and headquartered in Eindhoven, Netherlands, MicroSure is dedicated to enhancing patient outcomes through the development of advanced robotic systems. The company's flagship innovation, MUSA, represents the world's first surgical robot specifically engineered for open microsurgery. By providing superhuman precision, MUSA enables surgeons to perform complex interventions that were previously deemed impossible by manual means. The company operates at the intersection of deep tech and life sciences, maintaining a collaborative design philosophy that integrates the expertise of both seasoned microsurgeons and specialized engineers to ensure clinical efficacy and operational reliability.
How much funding has MicroSure raised?
MicroSure has raised a total of $46.1M across 3 funding rounds:
Series A
$3M
Series B
$3.2M
Other Financing Round
$39.9M
Series A (2018): $3M with participation from Innovation industries
Series B (2021): $3.2M led by Ten Cate Investeringsmaatschappij, BOM Brabant Ventures, Invest-NL, and Innovation Industries
Other Financing Round (2023): $39.9M, investors not publicly disclosed
Key Investors in MicroSure
Invest-NL
Invest-NL is the national financing and development institution dedicated to fostering a sustainable and innovative Netherlands, focusing on deep tech and life sciences.
Innovation Industries
Innovation Industries is a venture capital firm that focuses on high-tech and deep-tech investments, supporting companies with significant engineering and manufacturing potential.
BOM Brabant Ventures
BOM Brabant Ventures is the investment arm of the Brabant Development Agency, providing capital and strategic support to innovative startups and scale-ups in the Netherlands.
What's next for MicroSure?
With the recent influx of capital, MicroSure is well-positioned to accelerate the commercial deployment of its MUSA platform and expand its footprint within the global surgical robotics market. The company's strategic roadmap likely involves scaling manufacturing capabilities, pursuing additional regulatory clearances in key international markets, and investing in R&D to broaden the scope of MUSA's clinical applications. As the demand for minimally invasive and high-precision surgical solutions grows, MicroSure is poised to leverage its technological moat to capture significant market share, effectively bridging the gap between traditional microsurgical techniques and the future of automated, robot-assisted medical interventions.
See full MicroSure company page
